CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events.
Zehra Khatoon Rasool, Rajvi K. Shah, Ansharah E. Zinnia Batool et al.· Frontiers in Endocrinology· 0 citations
Background/Objectives: Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with diabetes, heart failure, and chronic kidney disease. Their association with perioperative outcomes after major cardiac procedures remains uncertain. Methods: In this retrospective cohort study using th...
Mirza Muhammad Hadeed Khawar, Faizan Ahmed, M. Elnashar et al.· Journal of Clinical Medicine· 0 citations
Indobufen-based DAPT was comparable, not superior, to aspirin plus clopidogrel across bleeding and ischaemic outcomes, with no signal of increased ischaemic risk.
Aparna Gopinath, Jungwook Heo, Afifa Fatima et al.· Journal of International Med...· 0 citations
LCC- and HF-related mortality declined overall, with descriptive subgroup variation by sex, race/ethnicity, urbanization, and geography, and targeted screening, hepatitis management, and equitable healthcare access are needed to address these patterns.
S. Khan, Muneeb Khawar, Muhammad Haris Khan et al.· ASIDE Gastroenterology· 0 citations
